The potential for serum p53 to predict the response to chemotherapy of patients with gastric cancer

Journal of International Medical Research

Volumn 38, Issue 2, 2010, Pages 423-431

  Zhang, J ^a,b   He, X H ^a   Xie, X Y ^a   Hu, X ^a,b   He, C ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b Key Laboratory of Biotherapy of Zhejiang Province   (China)

Author keywords

Chemotherapy; Chemotherapy marker; Gastric cancer; P53; Permeability glycoprotein (P GP)

Indexed keywords

GLYCOPROTEIN P; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STOMACH CANCER; TISSUE LEVEL; TREATMENT RESPONSE;

EID: 77953726298     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800205     Document Type: Article

References (30)

1. Catalano V, Labianca R, Beretta GD, et al: Gastric cancer. Crit Rev Oncol Hematol 2009; 71: 127-164.
2. Parkin DM: Epidemiology of cancer global patterns and trends. Toxicol Lett 1998; 102-103: 227-234.
3. Xu GW: Present status and problems in the treatment of gastric cancer.J Surg Concepts Practice 2003; 8: 3-6 [in Chinese].
4. Yeh KH, Cheng AL: Recent advances in therapy for gastric cancer.J Formos MedAssoc 2004; 103: 171-185.
5. Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric Junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004; 15:1773-1781.
6. Kamoshida S, Suzuki M, Shimomura R, et al Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer 2007; 96: 277-283.
7. Catalano V, Baldelli AM, Giordani P, et al. Molecular markers predictive of response to chemotherapy in gastrointestinal tumours. Crit Rev Oncol Hematol 2001; 38: 93-104.
8. Yonemura Y, Kinoshita K, Fujimura T, et al: Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology 1996; 43: 1260-1272.
9. Hamada M, Fujiwara T, Hizuta A, et al The p53 gene is a potent determinant of chemo-sensitivity and radiosensitivity in gastric and colorectal cancers.J Cancer Res Clin Oncol 1996; 122: 360-365.
10. Cascinu S, Graziano F, Ferro ED, et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998; 83: 1917-1922.
11. Nakata B, Chung KH, Ogawa M, et al p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today 1998; 28: 595-598.
12. Lenz HJ, Leichman CG, Danenberg KD, et al Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.J Clin Oncol 1996; 14: 176-182.
13. Yeh KH, Shun CT, Chen CL, et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998; 82: 1626-1631.
14. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.J Clin Oncol 1998; 16: 309-316.
15. Joshi AA, Wang Q, Stuttle DP: p53 modulation of DNA topoisomerase II gene expression. Cell Biochem Biophys 2000; 33: 209-216.
16. Quelle FW, Wang L, Feng J., et al: Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev 1998; 12: 1099-1107.
17. Deveci MS, Deveci G: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer 2007; 10: 112-116.
18. Vernhet L, Courtois A, Allain N, et al. Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells. FEBS Lett 1999; 443: 321-325.
19. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-4563.
20. Choi CH, Sun KH, An CS, et al Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3',4'-pentamethoxyflavone (Sinensetin). Biochem Biophys Res Commun 2002; 295: 832 -840.
21. Lee TB, Park JH, Min YD, et al. Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterol 2008; 8: 33.
22. Xie XY, Tan YJ, Zhu YL: Relation between mutant p53 and multidrug resistance in gastric cancer. Zhejiang Da Xue Xue Bao Ti Xue Ban 2006; 35: 91-98 [in Chinese].
23. Hamilton SR, Aaltonen LA (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon; IARC Press, 2000; pp 39-52.
24. Boku N, Ohtsu A, Yoshida S, et al. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol 2007; 37: 275-281.
25. Shi H, Lu D, Shu Y, et al Expression of multidrug resistance-related proteins p-glycoproteinglutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest 2008; 26: 344-351.
26. Oh SY, Kwon HC, Kim SH, et al. Clinico-pathologic significance of HIF-la, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008; 8:123.
27. Attallah AM, Abdel-Aziz MM, El-Sayed AM, et al. Detection of serum p53 protein in patients with different gastrointestinal cancers. Cancer Detect Prev 2003; 27: 127-131.
28. Brandt-Rauf PW, Chen JM, Marion MJ, et al. Conformational effects in the p53 protein of mutations induced during chemical carcino-genesis: molecular dynamic and immunologic analysis. J Protein Chem 1996; 15: 367-375.
29. Fontanini G, Fiore L, Bigini D, et al. Levels of p53 antigen in the serum of non-small cell lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections. Int J Oncol 1994; 54: 4855-4858.
30. Vojtesek B, Fisher CJ, Barnes DM, et al Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J.Cancer 1993; 67: 1254-1258.